SHANG.FOS.PHARM.GR.H YC 1 (08HH) - Total Liabilities

Latest as of March 2026: €59.30 Billion EUR ≈ $69.32 Billion USD

Based on the latest financial reports, SHANG.FOS.PHARM.GR.H YC 1 (08HH) has total liabilities worth €59.30 Billion EUR (≈ $69.32 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 08HH financial resilience to evaluate the company's liquid asset resilience ratio.

SHANG.FOS.PHARM.GR.H YC 1 - Total Liabilities Trend (2021–2025)

This chart illustrates how SHANG.FOS.PHARM.GR.H YC 1's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see SHANG.FOS.PHARM.GR.H YC 1 total assets.

SHANG.FOS.PHARM.GR.H YC 1 Competitors by Total Liabilities

The table below lists competitors of SHANG.FOS.PHARM.GR.H YC 1 ranked by their total liabilities.

Company	Country	Total Liabilities
Bonheur OL:BONHR	Norway	Nkr15.88 Billion
Jiangyin Hengrun Heavy SHG:603985	China	CN¥2.57 Billion
Tansun Technology Co Ltd SHE:300872	China	CN¥1.30 Billion
JK Tyre & Industries Limited NSE:JKTYRE	India	Rs99.36 Billion
Siam Global House Public Company Limited BK:GLOBAL	Thailand	฿14.40 Billion
Zhejiang Zuch Technology Co. Ltd. A SHE:301280	China	CN¥1.22 Billion
New Pacific Metals Corp TO:NUAG	Canada	CA$1.06 Million
WIN Semiconductors TWO:3105	Taiwan	NT$19.27 Billion

Liability Composition Analysis (2021–2025)

This chart breaks down SHANG.FOS.PHARM.GR.H YC 1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See SHANG.FOS.PHARM.GR.H YC 1 balance sheet quality to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.93	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.21	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.48	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how SHANG.FOS.PHARM.GR.H YC 1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for SHANG.FOS.PHARM.GR.H YC 1 (2021–2025)

The table below shows the annual total liabilities of SHANG.FOS.PHARM.GR.H YC 1 from 2021 to 2025.

Year	Total Liabilities	Change
2025-12-31	€58.21 Billion ≈ $68.06 Billion	+1.19%
2024-12-31	€57.53 Billion ≈ $67.25 Billion	+1.18%
2023-12-31	€56.85 Billion ≈ $66.47 Billion	+7.16%
2022-12-31	€53.05 Billion ≈ $62.03 Billion	+18.09%
2021-12-31	€44.93 Billion ≈ $52.52 Billion	--

About SHANG.FOS.PHARM.GR.H YC 1

F:08HH Germany Drug Manufacturers - Specialty & Generic

Market Cap

$1.15 Billion

€979.42 Million EUR

Market Cap Rank

#8393 Global

#1098 in Germany

Share Price

€1.77

Change (1 day)

+1.14%

52-Week Range

€1.66 - €3.22

All Time High

€4.65